Related Experiment Video
Updated: Jun 2, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Therapy in the early stage: incretins
1Diabetes, Nutrition and Metabolic Diseases Outpatient Unit, Emergency County Clinical Hospital, Târgu Mureş, Romania. simonacernea@yahoo.com
Diabetes Care
|April 29, 2011
Summary
Incretin-based therapies offer new hope for type 2 diabetes management. These treatments improve glucose control, promote weight loss, and protect vital insulin-producing cells, potentially halting disease progression.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Conventional type 2 diabetes drugs have limitations and side effects like weight gain and hypoglycemia.
- Complex pathological mechanisms of type 2 diabetes require novel therapeutic approaches.
Purpose of the Study:
- To review the mechanisms, benefits, and potential of incretin-based therapies for type 2 diabetes.
- To highlight the advantages of incretin mimetics and incretin enhancers over existing treatments.
Main Methods:
- Review of current literature on incretin-based therapies.
- Analysis of the pharmacological actions of incretin mimetics and enhancers.
- Evaluation of clinical outcomes including glucose control, weight, cardiovascular effects, and beta-cell function.
Main Results:
- Incretin-based therapies (GLP-1 receptor agonists and DPP-4 inhibitors) demonstrate significant glucose-lowering efficacy.
- These therapies promote weight loss or neutrality, inhibit glucagon secretion, and offer cardiovascular benefits with a low risk profile.
- Incretins protect and enhance beta-cell function by promoting proliferation, differentiation, and insulin secretion, while inhibiting apoptosis.
Conclusions:
- Incretin-based therapies represent a significant advancement in type 2 diabetes treatment.
- Early intervention with incretin-based therapies may preserve or restore beta-cell mass and function, potentially altering disease progression.
- These agents offer a favorable risk-benefit profile compared to conventional therapies.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...